These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3287837)

  • 21. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
    Vessby B; Lithell H; Gustafsson IB; Boberg J
    Atherosclerosis; 1980 Jan; 35(1):51-65. PubMed ID: 6989377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
    Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
    Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Value of lipid lowering drugs after myocardial infarction: results of the coronary drug project 1975 (author's transl)].
    Dubach UC
    Schweiz Rundsch Med Prax; 1975 Sep; 64(37):1167-8. PubMed ID: 1219703
    [No Abstract]   [Full Text] [Related]  

  • 26. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden.
    Rosengren A; Hagman M; Wedel H; Wilhelmsen L
    Eur Heart J; 1997 May; 18(5):754-61. PubMed ID: 9152645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined clofibrate--nicotinic acid treatment in ischemic heart disease.
    Rosenhamer G; Carlson LA
    Atherosclerosis; 1980 Sep; 37(1):129-42. PubMed ID: 7426081
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hyperlipidemia and coronary disease].
    Krikler DM
    Coeur Med Interne; 1976; 15(1):3-10. PubMed ID: 793762
    [No Abstract]   [Full Text] [Related]  

  • 29. [Serum lipid-lowering drugs following myocardial infarction].
    Schettler G
    Dtsch Med Wochenschr; 1975 Aug; 100(31):1611-2. PubMed ID: 168052
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
    Hoogwerf BJ; Peters JR; Frantz ID; Hunninghake DB
    Metabolism; 1985 Oct; 34(10):978-81. PubMed ID: 4046841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clofibrate for prevention of myocardial infarction.
    Med Lett Drugs Ther; 1973 Apr; 15(9):37-8. PubMed ID: 4704699
    [No Abstract]   [Full Text] [Related]  

  • 33. Cholesterol, coronaries, clofibrate and death.
    Oliver MF
    N Engl J Med; 1978 Dec; 299(24):1360-2. PubMed ID: 362204
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.
    Nikkilä EA; Viikinkoski P; Valle M; Frick MH
    Br Med J (Clin Res Ed); 1984 Jul; 289(6439):220-3. PubMed ID: 6430414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled trial of plasma lipid reduction in peripheral atherosclerosis--an interim report.
    Duffield RG; Miller NE; Jamieson CW; Lewis B
    Br J Surg; 1982 Jun; 69 Suppl():S3-5. PubMed ID: 7044467
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
    Hanefeld M; Hora C; Schulze J; Rothe G; Barthel U; Haller H
    Atherosclerosis; 1984 Oct; 53(1):47-58. PubMed ID: 6497944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hypolipidemic drugs on serum lipoproteins.
    Carlson LA; Olsson AG
    Prog Biochem Pharmacol; 1979; 15():238-57. PubMed ID: 224397
    [No Abstract]   [Full Text] [Related]  

  • 40. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.